Jean-Charles Soria to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Jean-Charles Soria has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
4.740
-
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209.
Score: 0.381
-
Osimertinib in EGFR Mutation-Positive Advanced NSCLC. N Engl J Med. 2018 03 29; 378(13):1262-1263.
Score: 0.372
-
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
Score: 0.363
-
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 11; 86:186-196.
Score: 0.360
-
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
Score: 0.360
-
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. Eur J Cancer. 2017 11; 85:155-157.
Score: 0.358
-
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017 03 13; 15(1):55.
Score: 0.346
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017 03 04; 389(10072):917-929.
Score: 0.343
-
Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:12-17.
Score: 0.342
-
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018 11 01; 4(11):1543-1552.
Score: 0.097
-
LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):66-73.e6.
Score: 0.097
-
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018 10; 52(4).
Score: 0.096
-
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 10 20; 36(30):2995-3006.
Score: 0.095
-
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. J Clin Invest. 2018 04 02; 128(4):1671-1687.
Score: 0.093
-
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
Score: 0.093
-
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
Score: 0.091
-
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017 10; 112:62-68.
Score: 0.089
-
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
Score: 0.089
-
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res. 2017 05 01; 77(9):2222-2230.
Score: 0.087
-
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017 Jun 20; 35(18):2018-2027.
Score: 0.087
-
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79(6):1257-1265.
Score: 0.087
-
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treat Rev. 2017 Apr; 55:83-95.
Score: 0.087
-
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. Lung Cancer. 2017 06; 108:72-74.
Score: 0.086
-
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
Score: 0.080
-
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol. 2016 Jan; 36(1):94-102.
Score: 0.080
-
Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004 Mar 22; 90(6):1222-9.
Score: 0.035
-
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018 02; 14(2):e1005965.
Score: 0.023
-
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
Score: 0.023